Pacific Biosciences of Californ (PACB) Stock Price & How to Invest

Pacific Biosciences of California makes DNA sequencing systems built around its HiFi long-read technology, which reads long, highly accurate stretches of DNA. Its high-throughput Revio system serves production genomics labs generating reference-quality genomes, while the newer benchtop Vega, a smaller and much cheaper instrument, aims to put HiFi long reads on more lab benches and introduce new users to the platform. Like most sequencing companies, PacBio runs a razor-and-blade model: it sells instruments, then earns recurring, higher-margin revenue from the consumables and reagents customers buy to run them. In Q1 2026 revenue was about $37.2 million, roughly flat year over year, as stronger consumables sales offset softer instrument and service revenue, and gross profit improved markedly from a gross loss a year earlier.

The company spent 2025 and early 2026 sharpening its focus on long reads. In January 2026 it sold the intellectual property behind its short-read (Onso) sequencing technology to Illumina for roughly $48 million in net cash, effectively exiting the short-read race to concentrate on HiFi. PacBio guided full-year 2026 revenue to about $165 million to $175 million, framed around continued consumables growth against persistent weakness in academic and government research funding. It remains unprofitable, with a non-GAAP net loss near $36 million in Q1 2026, but it ended the quarter with roughly $276 million in cash and investments and describes a gradual march toward cash-flow breakeven through gross-margin gains and flat-to-lower operating expenses.

The dominant risk is that PacBio is unprofitable and burning cash: it posted a non-GAAP net loss near $36 million in Q1 2026 and depends on reaching breakeven before its cash cushion is stressed. Demand is exposed to academic and government research funding, which has been weak and is largely outside the company's control, pressuring instrument sales. Competition is intense: Oxford Nanopore leads the benchtop long-read market Vega is entering, and Illumina dominates the far larger short-read market, so PacBio must keep winning on technology and price. Vega promotional pricing and component costs have weighed on margins, and as a small-cap genomics stock PACB is highly volatile, sensitive to each quarter's placements, guidance revisions, and shifts in research budgets.

6 analysts publish price targets on PACB, averaging $2.46 against a $1.40 price as of August 2026, or +75.7%. The published targets run from $1.50 to $3.00, a moderate spread, and the ratings split 4 buy, 2 hold, 1 sell. Over the last six months there has been 1 raise and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PACB forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Pacific Biosciences of Californ. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. HiFi long-read differentiation. PacBio's core edge is HiFi sequencing, which combines the length of long reads with accuracy closer to short-read platforms. The most optimistic published target, $3.00, assumes this works close to its best case.

The case against. The dominant risk is that PacBio is unprofitable and burning cash: it posted a non-GAAP net loss near $36 million in Q1 2026 and depends on reaching breakeven before its cash cushion is stressed. The most pessimistic target, $1.50, is roughly what PACB is worth if this bites instead.

Read the full bull and bear case on PACB, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Pacific Biosciences of Californ's investor relations page or your broker.

• Revenue (Q1 2026): ~$37.2 million, roughly flat year over year
• Full-year 2026 revenue guidance: ~$165 million to $175 million (company guidance)
• Profitability: Unprofitable; non-GAAP net loss ~$36 million (~$0.12 per share) in Q1 2026, narrower than a year earlier
• Gross margin: Improving; gross profit turned positive (~$12.8 million) from a gross loss a year earlier
• Cash and investments: ~$276 million at end of Q1 2026, aided by the ~$48 million Illumina short-read IP sale
• Market profile: Small-cap, pre-profit growth stock; valued on revenue growth and breakeven path, not earnings

Figures are approximate and tied to the asOf date; verify live numbers before acting. Because PacBio is unprofitable, standard earnings multiples like P/E do not apply, and the stock is typically valued on revenue growth, gross-margin trajectory, and how quickly it can reach cash-flow breakeven relative to its cash balance. That makes instrument placements, consumables pull-through, and quarterly guidance far more important to the story than any single accounting figure, and it keeps the stock volatile.

If you want PACB exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to PACB: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PACB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ARKG), which spreads the position across many companies. Or build it into a focused thematic portfolio, so PACB sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PACB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

PacBio is a speculative, unprofitable long-read sequencing play betting that HiFi accuracy and a cheaper benchtop instrument grow the installed base and recurring consumables toward breakeven. It rewards a genomics upcycle and punishes weak research funding, so the question is how much early-stage risk fits you.

Whether PACB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PACB a buy or a sell?, and where the stock could go from here in the PACB stock forecast.

For income investors, whether PACB pays a dividend and how the payout looks is covered in does PACB pay a dividend? And to weigh PACB against a peer, read the full side-by-side comparisons: PACB vs ILMN and PACB vs IP.